z-logo
Premium
Tissue and plasma carcinoembryonic antigen in early breast cancer a prognostic factor
Author(s) -
Mansour Edward G.,
Hastert Mary,
Park Chan Ho,
Koehler Karl A,
Petrelli Mary
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830401)51:7<1243::aid-cncr2820510712>3.0.co;2-a
Subject(s) - carcinoembryonic antigen , medicine , gastroenterology , breast cancer , stage (stratigraphy) , cancer , prospective cohort study , oncology , paleontology , biology
A prospective study of plasma and tissue carcinoembryonic antigen (P‐CEA and T‐CEA) levels in 63 patients with early (Stage I and II) breast cancer was undertaken to determine if the presence of CEA in tissue and/or plasma at the time of primary surgery can be used as a prognostic factor. Thirty‐two Stage I and 31 Stage II patients were evaluable with a median follow‐up time of 26 months: 29/63 were T‐CEA and/or P‐CEA positive while 34/63 were T‐CEA and P‐CEA negative; 9/63 were both T‐CEA and P‐CEA positive; 13/63 were P‐CEA positive alone, while 25/63 were T‐CEA positive alone; 5/29 T‐CEA and/or P‐CEA positive showed disease progression with a mean DFI of 11.8 months, compared with 0/34 T‐CEA and P‐CEA negative patients ( P < 0.02); 2/9 T‐CEA and P‐CEA positive compared with 0/34 negative patients progressed ( P < 0.01). There was a significant difference ( P < 0.05) between P‐CEA positive (3/13) patients with recurrence and P‐CEA negative (2/50). When T‐CEA positive patients (4/25) were compared with T‐CEA negative (1/38), the difference approaches significance. When the recurrences were analyzed with respect to CEA, estrogen receptor (ER) and nodal status, only in the CEA+ versus CEA– group was there a significant difference. The early data show that patients with positive T‐CEA and/or P‐CEA have a higher recurrence rate with probable poor prognosis. Prognosis correlates better with CEA status than with ER or nodal status.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here